Alkermes plc Stock News

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Str

Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The latest trading day saw Alkermes (ALKS) settling at $26.70, representing a -1.26% change from its previous close.

The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical breakthroug

The latest trading day saw Alkermes (ALKS) settling at $26.94, representing a -0.41% change from its previous close.

Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.

Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Alkermes (ALKS) closed the most recent trading day at $27.74, moving -1% from the previous trading session.

Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech

Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.

In the evolving stock market landscape, identifying growth stocks to buy that promise resilience and prosperity over the long haul is akin to finding treasures in a rough, dusty terrain. This article

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023.